Radioligand precursors

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC23004	PSMA-ligand-1 Featured	PSMA ligand-tubulysin compounds represent a cutting-edge approach to targeted cancer therapy, combining the precision of PSMA targeting with the potent cytotoxicity of tubulysin. This strategy holds significant promise for improving outcomes in prostate cancer and other PSMA-expressing malignancies, offering a highly specific and effective treatment option with reduced systemic toxicity. As research progresses, these compounds could play a transformative role in the field of oncology.
DC12287	delta-Valerobetaine Featured	Delta-Valerobetaine is a precursor of trimethylamine N-oxide (TMAO).
DC12162	PSMA-617 Featured	PSMA-617 is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM.
DC33611	PSMA-617 Linker Featured	Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is widely used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) due to its ability to deliver targeted radiation directly to PSMA-expressing cancer cells, minimizing damage to surrounding healthy tissues.
DC40061	DOTATATE Featured	DOTATATE is a powerful tool in nuclear medicine, enabling the diagnosis and treatment of somatostatin receptor-positive tumors, particularly neuroendocrine tumors. When labeled with radionuclides like Ga-68 or Lu-177, it provides highly sensitive imaging and targeted therapy, making it a cornerstone in the management of these cancers. Its theragnostic potential allows for personalized treatment strategies, improving patient outcomes.
DC40273	AV-105 Featured	AV-105 is a tosylate precursor compound derived from Florbetapir (18F), a radiolabeled styrylpyridine derivative referenced in patent WO2010078370A1 (Example 1.5). This precursor plays a crucial role in the synthesis of 18F-radiolabeled imaging agents, particularly for positron emission tomography (PET) applications.
DC40358	MK-6240 Precursor Featured	MK-6240 Precursor (6e) serves as a key intermediate in the synthesis of [18F]-MK-6240, a highly selective tau-targeting PET imaging agent. The radiolabeled compound, [18F]-MK-6240, is specifically designed for detecting neurofibrillary tangles (NFTs)—a hallmark pathology of Alzheimer’s disease and other tauopathies.
DC60103	PSMA11 Featured	PSMA-11 is a critical tool in nuclear medicine, enabling the synthesis of Ga-68-PSMA-11 for PET imaging of PSMA-expressing tumors. Its high specificity for PSMA, combined with the favorable properties of Ga-68, makes it a valuable diagnostic agent in the management of prostate cancer and potentially other malignancies.
DC46535	THK-5475(THK 5475) Featured	THK-5475(THK5475) is a precursor of THK-5470, a monoamine oxidase-B(MAO-B) imaging probe, could be used for neurological diseases study (from patent EP2019-846498).
DC50044	Edotreotide Featured	Edotreotide is a synthetic somatostatin analogue that is used in nuclear medicine for the diagnosis and research of certain types of cancers, particularly neuroendocrine tumors (NETs). Somatostatin is a peptide hormone that inhibits the release of several other hormones, and many neuroendocrine tumors overexpress somatostatin receptors (SSTRs), making them ideal targets for somatostatin analogues like edotreotide.
DC71440	FAP-2286 Featured	FAP-2286 is a highly promising FAP-targeting theranostic agent with potent affinity for FAP, versatile radionuclide coupling capabilities, and demonstrated antitumor activity. Its ability to serve as both a diagnostic imaging agent and a therapeutic tool makes it a valuable asset in oncology, particularly for cancers with prominent stromal involvement. As research progresses, FAP-2286 has the potential to significantly advance cancer diagnosis, treatment, and research, offering new hope for patients with FAP-expressing tumors.
DC65336	PSMA-1007 Featured	PSMA-1007 is a novel Glu-Ureido-based prostate-specific membrane antigen (PSMA) inhibitor designed for use in positron emission tomography (PET) imaging of prostate cancer. It belongs to the class of small-molecule PSMA inhibitors that specifically target PSMA, a transmembrane protein highly expressed in prostate cancer cells and the neovasculature of other solid tumors. PSMA-1007 is particularly notable for its favorable pharmacokinetic properties, including high tumor uptake and low urinary excretion, making it an excellent tool for prostate cancer diagnosis and staging.
DC65338	Pentixafor(CPCR4-2) Featured	Pentixafor is a synthetic, cyclic pentapeptide analog of stromal cell-derived factor-1 (SDF-1 or CXCL12), which is the natural ligand for the C-X-C chemokine receptor type 4 (CXCR4). CXCR4 is a chemokine receptor that plays a critical role in tumor growth, progression, invasiveness, and metastasis. Pentixafor is designed to target CXCR4, which is overexpressed in various cancers and is associated with poor differentiation and aggressive disease.
DC65339	HBED-CC-tris（tBu) ester Featured
DC65340	UAMC1110-NH2 Featured	UAMC1110-NH2 is a derivative of UAMC1110 (SP-13786) with an aminobutoxy group, making it a useful intermediate for synthesizing UAMC1110 conjugates. UAMC1110 is a potent and selective FAP inhibitor with low nanomolar potency and high specificity over related proteases. Together, UAMC1110-NH2 and UAMC1110 have significant potential for advancing FAP-targeted therapies, imaging agents, and research tools, particularly in cancer and fibrotic diseases.
DC65709	PS-13 precursor 19 Featured	PS-13 Precursor 19 is a critical intermediate in the synthesis of PS-13, a highly potent and selective COX-1 inhibitor. PS-13's exceptional selectivity for COX-1 over COX-2 makes it a promising compound for both therapeutic development and research applications focused on understanding COX-1-mediated processes.
DC65710	PS13 Featured	PS13 is a highly potent and selective COX-1 inhibitor, and its radiolabeled form, [¹¹C]PS13, is a promising PET radiotracer for imaging COX-1 expression in vivo. Its ability to selectively bind COX-1 in major organs, including the spleen, gastrointestinal tract, kidneys, and brain, makes it a valuable tool for studying COX-1-mediated processes in health and disease. This radiotracer has significant potential for advancing research and therapeutic development in COX-1-related conditions.
DC65839	MC1 Precursor Featured	Precursor of MC1, is a vital component in the synthesis of MC1, a selective and potent COX-2 inhibitor. Radiolabeled MC1, [¹¹C]MC1, serves as a promising PET radioligand for imaging COX-2 expression in vivo. Its high selectivity, combined with its ability to non-invasively visualize COX-2 in disease states, makes it a valuable tool for research and clinical applications, particularly in neuroinflammation, cancer, and drug development.
DC65841	MC1 Featured	MC1 is a selective and potent COX-2 inhibitor, and its radiolabeled form, [¹¹C]MC1, is a promising PET radiotracer for detecting COX-2 expression in vivo. Its ability to visualize COX-2 in neuroinflammation and other disease states makes it a valuable tool for research and therapeutic development, particularly in understanding and targeting COX-2-mediated processes in the brain.
DC66114	FAPI-46 Featured	FAPI-46 is a highly promising FAP-targeted radiotracer with superior tumor uptake and prolonged accumulation, making it an excellent tool for imaging a wide range of cancers. Its versatility, combined with its potential for theragnostic applications, positions FAPI-46 as a valuable asset in the field of oncology, enabling improved diagnosis, staging, and treatment monitoring for patients with FAP-expressing tumors.
DC60607	SL-25.1188 Featured	SL-25.1188 is a reversible MAO-B inhibitor with high brain uptake and slow plasma metabolism, making it a promising candidate for treating Alzheimer's dementia and aiding in smoking cessation. Its ability to modulate neurotransmitter levels in the brain positions it as a valuable therapeutic tool for addressing these challenging conditions.
DC66458	FAPI -14 Featured
DC60608	SL25.1188 precursor Featured	SL25.1188 Precursor is a key intermediate in the synthesis of SL25.1188, a reversible and selective MAO-B radioligand. The radiolabeled form, [¹¹C]SL25.1188, is a promising PET imaging agent for studying MAO-B in the brain, with applications in neurodegenerative disease research and drug development. Its reversible binding and high selectivity make it a valuable tool for understanding MAO-B's role in health and disease.
DC66459	NOTA-FAPI Featured	NOTA-FAPI is a FAP-targeted imaging probe with excellent tumor detection efficacy and imaging quality. Its high specificity for FAP, stable radiolabeling, and ability to visualize the tumor stroma make it a promising tool for tumor diagnosis, staging, and treatment monitoring. NOTA-FAPI has significant potential for advancing cancer imaging and therapy, particularly in cancers with a prominent stromal component.
DC66460	FAPI-4 Featured	FAPI-4 is a potent FAP inhibitor with significant applications in cancer research and diagnostics. Its radiolabeled form, ⁶⁸Ga-FAPI-4, is a promising PET/CT imaging agent for visualizing FAP-expressing tumors with excellent tumor-to-background contrast. This makes it a valuable tool for cancer diagnosis, staging, treatment monitoring, and therapeutic development, particularly in cancers with a prominent stromal component.
DC66461	SH-FAPI-4 Featured	SH-FAPI-4 is a specific fibroblast activation protein inhibitor (FAPI) compound that belongs to the FAPI family of molecules. SH-FAPI-4 is expected to selectively accumulate in FAP-positive tumors and disrupt the functions of cancer-associated fibroblasts (CAFs) within the tumor microenvironment. By inhibiting FAP activity, this compound aims to potentially slow tumor growth, enhance the efficacy of other cancer treatments, and modulate the tumor microenvironment.
DC66462	HYINC-FAPI-4 Featured	HYINC-FAPI-4 is a 99mTc-labeled derivative of fibroblast activation protein inhibitor (FAPI), specifically designed for single-photon emission computed tomography (SPECT) imaging of tumors expressing fibroblast activation protein (FAP). FAP is a key marker in the tumor stroma, which plays a critical role in tumor growth, invasion, and metastasis.
DC66463	FAPI-46-NOTA Featured	NOTA-FAPI-46 is an analogue of FAPI-46 (MedKoo Cat#207189). NOTA-FAPI-46 is useful in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP). NOTA-FAPI-46 can be used as a PET tracer for detection of diseases or disorders related to fibroblast activation protein.
DC66464	3BP-3940 Featured	3BP-3940 is a highly potent FAP-targeting peptide with significant potential in theranostics. Its ability to be coupled with diagnostic and therapeutic radionuclides makes it a versatile tool for tumor imaging, targeted therapy, and treatment monitoring. By focusing on the tumor stroma, 3BP-3940 offers a promising approach to improving cancer diagnosis and treatment, particularly for cancers with prominent stromal involvement. As research progresses, 3BP-3940 could play a key role in advancing precision oncology.
DC66465	Pentanedioate Featured	Pentanedioate is a valuable starting material for the synthesis of PSMA inhibitors due to its flexible structure and functional groups that mimic natural PSMA ligands. By leveraging its chemical properties, researchers can develop potent and selective PSMA-targeting agents for diagnostic imaging, targeted therapy, and theranostic applications in prostate cancer and other PSMA-expressing malignancies. Its role in drug discovery highlights the importance of simple organic molecules in the development of advanced cancer therapies.

Radioligand precursors

Customized Consultation X

Your information is safe with us. * Required Fields.